Biotechnology

A novel biologic therapy from Immunis shows significant gains in walking speed for obese seniors, hinting at a new frontier in treating age-related decline.

With major funding and a seasoned CEO, Caldera Therapeutics is advancing a first-in-class bispecific antibody into the clinic for inflammatory bowel disease.

As BD enters a new growth phase with interim leadership, the MedTech giant brings in Shawn Bevec, whose unique background bridges lab science and Wall Street.

A new AI solution promises to automate a critical manufacturing step, tackling costly errors and downtime that plague the life sciences industry.

With new data showing six-month efficacy and a unique liquid formula, Galderma's Relfydess is poised to challenge established players in the neuromodulator space.

Dr. Toby Kiers wins the Tyler Prize for her work on fungi, as her NGO launches a new program to legally protect these vital underground ecosystems.

A new partnership aims to bring a revolutionary, disease-modifying stem cell therapy for knee osteoarthritis to millions of patients in Greater China.

With new funding from BroadOak Capital Partners, Axol Bioscience is set to expand its revolutionary iPSC-based disease models in the US market.

Moving beyond hype, ArisGlobal's record growth and enterprise adoption of its NavaX AI show the pharmaceutical industry is now operationalizing AI at scale.

With a new finance head, the non-profit plans to launch a breakthrough vitamin A product in Africa, blending philanthropy with commercial strategy.

The biopharma firm projects massive sales from its current drugs and bets big on a new Alzheimer's therapy, signaling a pivotal year of growth and innovation.

Propanc Biopharma is taking a 100-year-old cancer treatment concept into modern human trials, targeting advanced tumors and expanding into fibrosis.

A novel vaccine protects shrimp by immunizing their parents, offering a solution to devastating outbreaks and a path to sustainable global protein production.

MedTech firm Lifeward is acquiring Oramed's oral insulin tech, despite a past trial failure, in a high-stakes deal that could redefine both companies.

A new partnership aims to tackle the growing global health crisis of invasive fungal infections, a silent killer claiming millions of lives annually.

As Disc Medicine nears a potential drug launch, its new HR chief hire reveals a critical strategy for navigating biotech's intense talent wars.

The biotech firm faces a delisting threat after its equity turned negative. Can recent funding save its Nasdaq spot and its ambitious drug pipeline?

Adimab's stellar 2025 reveals its crucial role as the hidden tech platform driving drug discovery for giants like Lilly and Regeneron.

Pimicotinib, a once-daily pill for tenosynovial giant cell tumor, gains FDA review, offering new hope for patients beyond invasive surgery.

Cosmetics brand Sorevna is diving into the crowded bath and body sector, promising a revolutionary launch. But can its science-first approach succeed?